Bruce Madsen, MD
Ophthalmology · Albany, ORNPI 1760429831
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,214 of the $9,944 with a category attached, or 62.5%. 23 manufacturers reported payments, led by Ivantis, Inc at 25.3% of the total. Among ophthalmology clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 183 payments — averaging $54.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ivantis, Inc$3K
- Alcon$2K
- Microsurgical Technology, Inc.$1K
- Rxsight Inc$704
- Sun Pharmaceutical Industries Inc.$695
- Glaukos Corporation$587
- plus $2K from 17 others
Across 5 payments — averaging $63.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alcon Research LLC$319
What the payments were for
- Consulting fees$2,50025%
- Speaking & faculty fees$511%
- Food & beverage$6,21462%
- Education$240%
- Gifts$641%
- Charitable contribution$1,09011%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ivantis, Inc | 2 | $2,512 |
| Alcon | 30 | $2,070 |
| Microsurgical Technology, Inc. | 1 | $1,090 |
| Rxsight Inc | 13 | $704 |
| Sun Pharmaceutical Industries Inc. | 46 | $695 |
| Glaukos Corporation | 12 | $587 |
| AbbVie(2 entities) | 20 | $517 |
| NEW World Medical,inc. | 13 | $398 |
| Carl Zeiss Meditec USA, Inc. | 1 | $221 |
| Amgen(2 entities) | 4 | $217 |
| Johnson & Johnson Surgical Vision, Inc. | 9 | $178 |
| Biotissue Holdings Inc. | 3 | $144 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 7 | $141 |
| Aerie Pharmaceuticals, Inc. | 5 | $89 |
| Rayner Intraocular Lenses Limited | 4 | $78 |
| Sight Sciences, Inc. | 1 | $67 |
| Oyster Point Pharma, Inc. | 2 | $63 |
| Bausch & Lomb Americas Inc. | 3 | $60 |
| Kala Pharmaceuticals, Inc. | 2 | $29 |
| ANI Pharmaceuticals, Inc. | 2 | $28 |
| Merz Pharmaceuticals, LLC | 1 | $24 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Novartis | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Hydrus Microstent$2,500
- ARGOS$507
- Clareon$478
- RXSIGHT CONTACT LENS$327
- RXSIGHT INJECTOR CARTRIDGE$327
- RXSIGHT INJECTOR HANDPIECE$327
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$327
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$226
- iDoseTR$221
- IOLMaster 700$221
- LUMERA$221
- VERACITY SURGICAL$221
- QUATERA 700$221
- TEPEZZA$148
- AcrySof IQ PanOptix UV IOL$144
- Wavelight Refractive Suite$101
- LIGHT ADJUSTABLE LENS (LAL)$100
How this compares
$9,944 in reported general payments places this provider in the 95th percentile of 248 ophthalmology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 36 | $18,540 |
| VyzultaLatanoprostene Bunod | 15 | $9,928 |
| CombiganBrimonidine Tartrate/Timolol | 17 | $7,080 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 27 | $6,313 |
| RocklatanNetarsudil Mesylat/Latanoprost | 14 | $5,821 |
| Prednisolone Acetate | 72 | $3,282 |
| Brimonidine Tartrate | 29 | $1,558 |
| Latanoprost | 130 | $1,435 |
| Ketorolac Tromethamine | 48 | $1,242 |
| Timolol Maleate | 77 | $871 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 61 | $741 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 40 | $625 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan | $517 | $25,62053 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $60 | $9,92815 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $89 | $5,82114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 248 ophthalmology providers in Oregon.
Other ophthalmology in Albany
- David HuangCorvallis$67K
- Mark PennesiPortland$56K
- Rene ChoiPortland$21K
- Balamurali AmbatiEugene$19K
- Richard HoffmanEugene$17K
- Bart AdamsPendleton$17K
- Richard WeleberPortland$14K
- Aazim SiddiquiPortland$13K
- Kurt AndreasonBend$13K
- Poorav PatelMedford$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.